Toward individualized pharmaceutical care of East Asians: The value of genetic testing for polymorphisms in drug-metabolizing genes

Pharmacogenomics

Volumn 5, Issue 6, 2004, Pages 673-689

  Morrison, Alan ^a   Levy, Richard ^b  

^a SCRIBCO   (United States)

^b National Pharmaceutical Council   (United States)

Author keywords

Arylamine N acetyltransferase; Cytochrome P450; Drug metabolism; East Asians; Gene frequency; Pharmacokinetics; Polymorphism; Poor metabolizer

Indexed keywords

AMINOBENZOIC ACID DERIVATIVE; AMINOSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ARYLAMINE ACETYLTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CLONAZEPAM; CYTOCHROME P450; CYTOCHROME P450 2C9; DAPSONE; DRUG METABOLIZING ENZYME; GLIPIZIDE; HALOPERIDOL; HYDRALAZINE; ISONIAZID; LITHIUM; LOSARTAN; NEUROLEPTIC AGENT; PHENYTOIN; PROCAINAMIDE; PROPRANOLOL; PROTON PUMP INHIBITOR; SULFADIMIDINE; SULFONAMIDE; TOLBUTAMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; WARFARIN;

AGE; ASIAN; BODY WEIGHT; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG RESPONSE; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE FUNCTION; GENE INACTIVATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SCREENING; HEPATITIS; HUMAN; INDIVIDUALIZATION; LIVER TOXICITY; PHARMACEUTICAL CARE; PHARMACOGENETICS; PHENOTYPE; PREDICTION; REVIEW; TUBERCULOSIS;

ARYLAMINE N-ACETYLTRANSFERASE; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; FAR EAST; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS;

EID: 4544276682     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.6.673     Document Type: Review

References (112)

1. Rosenberg NA, Pritchard JK, Weber JL et al.: Genetic structure of human populations. Science 298(5602), 2381-2385 (2002).
2. Barnes JS, Bennett CE: The Asian population: 2000. Census 2000 Brief US Census Bureau (2002).
3. Yu HC, Chan TY, Critchley JA, Woo KS: Factors determining the maintenance dose of warfarin in Chinese patients. QJM 89(2), 127-135 (1996).
4. Ross AM, Gao R, Coyne KS et al.: A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial. Am. Heart J. 142(2), 244-247 (2001).
5. Wood AJ, Zhou HH: Ethnic differences in drug disposition and responsiveness. Clin. Pharmacokinet. 20(5), 350-373 (1991).
6. Poolsup N, Li Wan Po A, Knight TL: Pharmacogenetics and psychopharmacotherapy. J. Clin. Pharm. Ther. 25(3), 197-220 (2000).
7. Lin KM, Cheung F: Mental health issues for Asian Americans. Psychiatr. Serv. 50(6), 774-780 (1999).
8. Meyer UI: Drugs in special patient groups: clinical importance of genetics in drug effects. In: Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics (3rd edn). Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW (Eds), McGraw-Hill, Inc., New York 875-894 (1992).
9. Miners JO, Birkett DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45(6), 525-538 (1998).
10. Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann. Rev. Pharmacol. Toxicol. 37, 269-296 (1997).
11. Hein DW, Doll MA, Fretland AJ et al.: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. 9(1), 29-42 (2000).
12. Dahl ML, Sjoqvist F: Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther. Drug Monit. 22(1), 114-117 (2000).
13. Goldstein JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily Br. J. Clin. Pharmacol. 52(4), 349-355 (2001).
14. Raunio H, Rautio A, Gullsten H, Pelkonen O: Polymorphisms of CYP2A6 and its practical consequences. Br. J. Clin. Pharmacol. 52(4), 357-363 (2001).
15. Desta Z, Zhao X, Shin JG, Flockhart DA: Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41(12), 913-958 (2002).
16. Rogers JF, Nafziger AN, Bertino JS Jr: Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am. J. Med. 113(9), 746-750 (2002).
17. Lee CR, Goldstein JA, Pieper JA: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12(3), 251-263 (2002).
18. Rodrigues AD, Rushmore TH: Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr. Drug Metab. 3(3), 289-309 (2002).
19. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3(2), 229-243 (2002).
20. Rautio A: Polymorphic CYP2A6 and its clinical and toxicological significance. Pharmacogenomics J. 3(1), 5-7 (2003).
21. US Preventive Services Task Force: Guide to Clinical Preventive Services (2nd edn). Department of Health and Human Services, Office of Disease Prevention and Health Promotion, Washington, DC (1996).
22. Lewis DF: P450 structures and oxidative metabolism of xenobiotics. Pharmacogenomics 4(4), 387-395 (2003).
23. Zanger UM, Fischer J, Raimundo S et al.: Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP21D6. Pharmacogenetics 11(7), 573-585 (2001).
24. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286(5439), 487-491 (1999).
25. Zhao B, Seow A, Lee EJ, Lee HP: Correlation between acetylation phenotype and genotype in Chinese women. Eur. J. Clin. Pharmacol. 56(9-10), 689-692 (2000).
26. Rothman N, Hayes RB, Bi W et al.: Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 3(5), 250-255 (1993).
27. Okumura K, Kita T, Chikazawa S, Komada F, Iwakawa S, Tanigawara Y: Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clin. Pharmacol. Ther. 61(5), 509-517 (1997).
28. Kita T, Tanigawara Y, Chikazawa S et al.: N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol. Pharm. Bull. 24(5), 544-549 (2001).
29. Ohno M, Yamaguchi I, Yamamoto I et al: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 4(3), 256-261 (2000).
30. Huang YS, Chern HD, Su WJ et al.: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35(4), 883-889 (2002).
31. Huang YS, Chern HD, Su WJ et al.: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37(4), 924-930 (2003).
32. Caraco Y, Muszkat M, Wood AJ: Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics 11(7), 587-596 (2001).
33. Takahashi H, Echizen H: Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J. 3(4), 202-214 (2003).
34. Leung AY, Chow HC, Kwong YL et al.: Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 98(8), 2584-2587 (2001).
35. Yoon YR, Shon JH, Kim MK et al.: Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol. 51(3), 277-280 (2001).
36. Daly AK, Day CP, Aithal GP: CYP2C9 polymorphism and warfarin dose requirements. Br. J. Clin. Pharmacol. 53(4), 408-409 (2002) (Letter).
37. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353(9154), 717-719 (1999).
38. Higashi MK, Veenstra DL, Kondo LM et al.: Association between CYP20 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13), 1690-1698 (2002).
39. Margaglione M, Colaizzo D, D'Andrea G et al.: Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 84(5), 775-778 (2000).
40. Taube J, Halsall D, Baglin T: Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of overanticoagulation in patients on long-term treatment. Blood 96(5), 1816-1819 (2000).
41. Takahashi H, Kashima T, Nomizo Y et al.: Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin. Pharmacol. Ther. 63(5), 519-528 (1998).
42. Takahashi H, Wilkinson GR, Caraco Y et al.: Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther. 73(3), 253-263 (2003).
43. James AH, Britt RP, Raskino CL, Thompson SG: Factors affecting the maintenance dose of warfarin. J. Clin. Pathol. 45(8), 704-706 (1992).
44. Wells PS, Holbrook AM, Crowther NR, Hirsh J: Interactions of warfarin with drugs and food. Ann. Intern. Med. 121(9), 676-683 (1994).
45. Loebstein R, Yonath H, Peleg D et al.: Interindividual variability in sensitivity to warfarin - nature or nurture? Clin. Pharmacol. Ther. 70(2), 159-164 (2001).
46. Shikata E, Ieiri I, Ishiguro S et al.: Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103(7), 2630-2635 (2004).
47. Takahashi H, Wilkinson GR, Padrini R, Echizen H: CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. Clin. Pharmacol. Ther. 75(5), 376-380 (2004).
48. Goldstein JA, de Morais SM: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4(6), 285-299 (1994).
49. Ferguson RJ, De Morais SM, Benhamou S et al.: A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther. 284(1), 356-361 (1998).
50. Xiao ZS, Goldstein JA, Xie HG et al.: Differences in the incidence of the CYP209 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther. 281(1), 604-609 (1997).
51. He N, Yan FX, Huang SL et al.: CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population. Eur. J. Clin. Pharmacol. 58(1), 15-18 (2002).
52. Ibeanu GC, Blaisdell J, Ferguson RJ et al.: A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J. Pharmacol. Exp. Ther. 290(2), 635-640 (1999).
53. Ibeanu GC, Blaisdell J, Ghanayem BI et al.: An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 8(2), 129-135 (1998).
54. Ibeanu GC, Goldstein JA, Meyer U et al.: Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J. Pharmacol. Exp. Ther. 286(3), 1490-1495 (1998).
55. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L: CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 6(6), 547-551 (1996).
56. Sagar M, Tybring G, Dahl ML, Bertilsson L, Seensalu R: Effects of omeprazole on intragastric PH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 119(3), 670-676 (2000).
57. Egan LJ, Myhre GM, Mays DC, Dierkhising RA, Kammer PP, Murray JA: CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastrooesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment. Pharmacol. Ther. 17(12), 1521-1528 (2003).
58. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T: Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5(2), 181-202 (2004).
59. Furuta T, Ohashi K, Kamata T et al.: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med. 129(12), 1027-1030 (1998).
60. Chong E, Ensom MH: Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 23(4), 460-471 (2003).
61. Sohn DR, Kwon JT, Kim HK, Ishizaki T: Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin. Pharmacol. Ther. 61(5), 574-582 (1997).
62. Sakai T, Aoyama N, Kita T et al.: CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm. Res. 18(6), 721-727 (2001).
63. Miki I, Aoyama N, Sakai T et al.: Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur. J. Gastroenterol. Hepatol. 15(1), 27-33 (2003).
64. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A: Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 53(2), 111-122 (2002).
65. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K: Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol. 50(1), 31-34 (2000).
66. Ji L, Pan S, Marti-Jaun J, Hanseler E, Rentsch K, Hersberger M: Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin. Chem. 48(7), 983-988 (2002).
67. Sachse C, Brockmoller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60(2), 284-295 (1997).
68. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S: Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin. Pharmacol. Ther. 65(5), 570-575 (1999).
69. Nishida Y, Fukuda T, Yamamoto I, Azuma J: CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 10(6), 567-570 (2000 ).
70. Nakamura K, Ariyoshi N, Yokoi T et al.: CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. Biochem. Biophys. Res. Commun. 293(3), 969-973 (2002).
71. Ramamoorthy Y, Tyndale RF, Sellers EM: Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11(6), 477-487 (2001).
72. Yu A, Kneller BM, Rettie AE, Haining RL: Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J. Pharmacol. Exp. Ther. 303(3), 1291-1300 (2002).
73. Tseng CY, Wang SL, Lai MD, Lai ML, Huang JD: Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin. Pharmacol. Ther. 60(2), 177-182 (1996).
74. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L: Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 6(5), 441-447 (1996).
75. Huang J, Chuang SK, Cheng CL, Lai ML: Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clin. Pharmacol. Ther. 65(4), 402-407 (1999).
76. Yue QY, Zhong ZH, Tybring G et al.: Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin. Pharmacol. Ther. 64(4), 384-390 (1998).
77. Yokono A, Morita S, Someya T, Hifokane G, Okawa M, Shimoda K: The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. J. Clin. Pychopharmacol. 21(6), 549-555 (2001).
78. Shimoda K, Someya T, Yokono A et al.: The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J. Clin. Psychopharmacol. 22(4), 371-378 (2002).
79. Jiang ZP, Shu Y, Chen XP et al.: The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. Eur. J. Clin. Pharmacol. 58(2), 109-113 (2002).
80. Suzuki A, Otani K, Mihara K et al.: Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetic 7(5), 415-418 (1997).
81. Mihara K, Suzuki A, Kondo T et al.: Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin. Pharmacol. Ther. 65(3), 291-294 (1999).
82. Roh HK, Chung JY, Oh DY et al.: Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br. J. Clin. Pharmacol. 52(3), 265-271 (2001).
83. Shimoda K, Morita S, Yokono A et al.: CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients. Ther. Drug Monit. 22(4), 392-396 (2000).
84. Someya T, Suzuki Y, Shimoda K et al.: The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population. Psychiatry Clin. Neurosci. 53(5), 593-597 (1999).
85. Someya T, Shimoda K, Suzuki Y et al.: Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. Neuropsychopharmacology 28(8), 1501-1505 (2003).
86. Ariyoshi N, Sekine H, Saito K, Kamataki T: Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese. Pharmacogenetics 12(6), 501-504 (2002).
87. Ando M, Hamajima N, Ariyoshi N, Kamataki T, Matsuo K, Ohno Y: Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults. J. Epidemiol. 13(3), 176-181 (2003).
88. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M: Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun. 284(2), 455-460 (2001).
89. Xu C, Rao YS, Xu B et al.: An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem. Biophys. Res. Commun. 290(1), 318-324 (2002).
90. Daigo S, Takahashi Y, Fujieda M et al.: A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 12(4), 299-306 (2002).
91. Nunoya KI, Yokoi T, Kimura K et al.: A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J. Pharmacol. Exp. Ther. 289(1), 437-442 (1999).
92. Sellers EM, Tyndale RF, Fernandes LC: Decreasing smoking behaviour and risk through CYP2A6 inhibition. Drug Discov. Today 8(11), 487-493 (2003).
93. Rao Y, Hoffmann E, Zia M et al.: Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol. 58(4), 747-755 (2000).
94. Ariyoshi N, Miyamoto M, Umetsu Y et al.: Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol. Biomarkers Prev. 11 (9), 890-894 (2002).
95. Minematsu N, Nakamura H, Iwata M et al.: Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema. Thorax 58(7), 623-628 (2003).
96. Loriot MA, Rebuissou S, Oscarson M et al.: Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics 11 (1), 39-44 (2001).
97. Tan W, Chen GF, Xing DY, Song CY, Kadlubar FF, Lin DX: Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int. J. Cancer 95(2), 96-101 (2001).
98. Tricker AR: Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. Toxicology 183(1-3), 151-173 (2003).
99. Sellers EM, Tyndale RF: Mimicking gene defects to treat drug dependence. Ann. NY Acad. Sci. 909, 233-246 (2000).
100. Fernandes LC, Kilicarslan T, Kaplan HL, Tyndale RF, Sellers EM, Romach MK: Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. J. Clin. Psychopharmacol. 22(3), 326-329 (2002).
101. Chou WH, Yan FX, Robbins-Weilert DK et al.: Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin. Chem. 49(4), 542-551 (2003).
102. McElroy S, Sachse C, Brockmoller J et al.: CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS PharmSci 2(4), E33 (2000).
103. Sox HC, Blatt MA, Higgins MC, Marton KI: Medical Decision Making. Butterworth-Heinemann, Newton, MA, USA (1988).
104. Marx J: Medicine. Why a new cancer drug works well, in some patients. Science 304(5671), 658-659 (2004).
105. Green MR: Targeting targeted therapy. N. Engl. J. Med. 350 (21), 2191-2193 (2004).
106. Murphy MP, Beaman ME, Clark LS et al.: Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a Phase III clinical trial. Pharmacogenetics 10(7), 583-590 (2000).
107. Kukongviriyapan V, Prawan A, Tassaneyakul W, Aiemsa-Ard J, Warasiha B: Arylamine N-acetyltransferase-2 genotypes in the Thai population. Br. J. Clin. Pharmacol. 55(3), 278-281 (2003).
108. Tassaneeyakul W, Tawalee A, Tassaneeyakul W et al.: Analysis of the CYP2C19 polymorphism in a north-eastern Thai population. Pharmacogenetics 12(3), 221-225 (2002).
109. Kubota T, Chiba K, Ishizaki T: Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 60(6), 661-666 (1996).
110. Goldstein JA, Ishizaki T, Chiba K et al.: Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7(1), 59-64 (1997).
111. Dahl ML, Yue QY, Roh HK et al.: Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 5(3), 159-164 (1995).
112. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M: Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46(3), 452-459 (1994).